Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alkermes (NASDAQ:ALKS – Get Free Report) will issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.61 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. Alkermes (NASDAQ:ALKS – Get Free […]
AN EXPERIENCED pharmaceutical industry leader has been appointed as Director of the Pharmaceutical Manufacturing Technology Centre at UL.
HRMY earnings call for the period ending March 31, 2024.
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency